Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2020

Franceschi Enrico, Tosoni Alicia, Bartolini Stefania, Minichillo Santino, Mura Antonella, Asioli Sofia, Bartolini Daniela, Gardiman Marina, Gessi Marco, Ghimenton Claudio, Giangaspero Felice, Lanza Giovanni, Marucci Gianluca, Novello Mariangela, Silini Enrico M, Zunarelli Elena, Paccapelo Alexandro, Brandes Alba A

Abstract excerpt

BACKGROUND: Diffuse grade II and grade III gliomas are actually classified in accordance with the presence of isocitrate dehydrogenase mutation (IDH-mut) and the deletion of both 1p and 19q chromosome arms (1p/19q codel). The role of tumour grading as independent prognostic factor in these group of tumours remains matter of debate. The aim of this study was to determine if grade is an independent prognostic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioma

Share to Mutation

Share to Neoplasm Grading

Share to Young Adult

Source

Identifiers

PMID: 32721633
DOI: 10.1016/j.ejca.2020.06.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.PMID 32721633Read ↗

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Semantic proximity Read ↗

IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.Semantic proximity Read ↗

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.Semantic proximity Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Semantic proximity Read ↗

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.Semantic proximity Read ↗

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.Semantic proximity Read ↗

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.Semantic proximity Read ↗

Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.Semantic proximity Read ↗

Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.